139 related articles for article (PubMed ID: 37730293)
1. Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week.
Verbeeck J; De Backer M; Verwerft J; Salvaggio S; Valgimigli M; Vranckx P; Buyse M; Brunner E
J Am Coll Cardiol; 2023 Sep; 82(13):1360-1372. PubMed ID: 37730293
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.
Verbeeck J; Spitzer E; de Vries T; van Es GA; Anderson WN; Van Mieghem NM; Leon MB; Molenberghs G; Tijssen J
Stat Med; 2019 Dec; 38(30):5641-5656. PubMed ID: 31659790
[TBL] [Abstract][Full Text] [Related]
4. Composite endpoints, including patient reported outcomes, in rare diseases.
Verbeeck J; Dirani M; Bauer JW; Hilgers RD; Molenberghs G; Nabbout R
Orphanet J Rare Dis; 2023 Sep; 18(1):262. PubMed ID: 37658423
[TBL] [Abstract][Full Text] [Related]
5. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials.
Cui Y; Dong G; Kuan PF; Huang B
J Biopharm Stat; 2023 May; 33(3):272-288. PubMed ID: 36343174
[TBL] [Abstract][Full Text] [Related]
6. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints.
Deltuvaite-Thomas V; Burzykowski T
Pharm Stat; 2022 Jan; 21(1):122-132. PubMed ID: 34346169
[TBL] [Abstract][Full Text] [Related]
9. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
10. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
[TBL] [Abstract][Full Text] [Related]
11. Mixed exercise training for adults with fibromyalgia.
Bidonde J; Busch AJ; Schachter CL; Webber SC; Musselman KE; Overend TJ; Góes SM; Dal Bello-Haas V; Boden C
Cochrane Database Syst Rev; 2019 May; 5(5):CD013340. PubMed ID: 31124142
[TBL] [Abstract][Full Text] [Related]
12. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
Bakal JA; Westerhout CM; Armstrong PW
Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
[TBL] [Abstract][Full Text] [Related]
13. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Pocock SJ; Ariti CA; Collier TJ; Wang D
Eur Heart J; 2012 Jan; 33(2):176-82. PubMed ID: 21900289
[TBL] [Abstract][Full Text] [Related]
14. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
[TBL] [Abstract][Full Text] [Related]
15. Subacromial decompression surgery for rotator cuff disease.
Karjalainen TV; Jain NB; Page CM; Lähdeoja TA; Johnston RV; Salamh P; Kavaja L; Ardern CL; Agarwal A; Vandvik PO; Buchbinder R
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD005619. PubMed ID: 30707445
[TBL] [Abstract][Full Text] [Related]
16. Use of win time for ordered composite endpoints in clinical trials.
Troendle JF; Leifer ES; Yang S; Jeffries N; Kim DY; Joo J; O'Connor CM
Stat Med; 2024 May; 43(10):1920-1932. PubMed ID: 38417455
[TBL] [Abstract][Full Text] [Related]
17. Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components.
Liao R; Chakladar S; Gamalo M
Pharm Stat; 2022 Nov; 21(6):1342-1356. PubMed ID: 35766113
[TBL] [Abstract][Full Text] [Related]
18. The Net Benefit of a treatment should take the correlation between benefits and harms into account.
Buyse M; Saad ED; Peron J; Chiem JC; De Backer M; Cantagallo E; Ciani O
J Clin Epidemiol; 2021 Sep; 137():148-158. PubMed ID: 33774140
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]